ClinicalTrials.gg
RecruitingNCT03131427Updated Apr 27, 2017

China Registry for Genetic / Metabolic Liver Diseases

An observational study in Genetic/Metabolic Liver Diseases, sponsored by Beijing Friendship Hospital. Recruiting at 12 sites in China. Per ClinicalTrials.gov, last updated 2017-04-27.

Sponsored by Beijing Friendship Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2022, 4 years 6 months ago, but the record still lists the study as recruiting.
  • Started Jun 2015; still recruiting 11 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Hepatolenticular Degeneration with a site in China — 10 open to participants now, 11 under way, 1 of them phase 3. Hepatolenticular Degeneration · China.

Started
2015
the only one that year
Observational
6 of 15
4 open now
Primary completion
2022-04
later than 0 of 10 live
Registered
1st of 15
by date
Lead sponsor
1 of 15
Beijing Friendship Hospital

Among the 15 studies in Hepatolenticular Degeneration with a site in China, this one is the only one that started in 2015, is one of 6 observational ones, reaches primary completion later than 0 of the 10 other live ones, and was the 1st registered.

Hepatolenticular Degeneration

80 studies on the registry are indexed under Hepatolenticular Degeneration; 31 are open to participants now.

Browse Hepatolenticular Degeneration studies →

Open to participants now

10 of the 15 studies in Hepatolenticular Degeneration with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 22 Hepatolenticular Degeneration studies recruiting now, 17 (77%) set no upper age limit and 4 (18%) stop at 75 or younger; 14 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hepatolenticular Degeneration with a site in China, or all of them as a file.
02

Study summary

CR-GMLD registry started on June 13, 2015 to collect cases of genetic/metabolic liver diseases from tertiary or secondary hospitals in mainland China. Demographics, diagnosis, laboratory test results, family history and prescriptions were recorded. Patients' whole blood and serum were collected for genetic testing and future researches. These patients will be followed-up every six to twelve months.

Read the detailed description

This web-based database was launched on June 13, 2015 and consists of tertiary or secondary hospitals with special interest and expertise on managing genetic/metabolic liver diseases patients across mainland China. The main inclusion criteria for this registration are patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases. At the first time of data entry, demographics, medical history, biochemistry and hematology results, radiology reports, diagnosis and treatment information were recorded. Patients' whole blood and serum were collected for molecular genetic testing and future researches. Then the registered patients will receive standard of care and be followed-up every 6 to 12 months. On each visit, biochemical, radiological reports, as well as clinical progress were recorded.

03

Conditions studied

  • Genetic/Metabolic Liver Diseases

Keywords

  • Wilson's Disease
  • Hereditary Hemochromatosis
  • Hereditary Hyperbilirubinemias
  • Inherited Cholestatic Liver Disease
  • Genetic Testing
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry is a multicenter and observational study enrolling patients with genetic/metabolic liver disease across mailand China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who were diagnosed or possibly diagnosed with Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias, inherited cholestatic liver disease or other genetic/metabolic liver diseases.

Exclusion criteria

Exclusion Criteria:

Patients who are unable or unwilling to provide .

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Wilson's Disease

    Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.

    Drug: Standard of care

  • Hereditary Hemochromatosis

    Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.

    Drug: Standard of care

  • Hereditary Hyperbilirubinemias

    Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).

    Drug: Standard of care

  • Inherited Cholestatic Liver Disease

    Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).

    Drug: Standard of care

  • Other genetic/metabolic liver diseases

    Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.

    Drug: Standard of care

Interventions

  • DrugStandard of care

    Standard of care according to the updated national and/or international guidelines

06

What researchers measure

Primary outcomes

  1. rate of liver-related events of each disease.

    Rates of cirrhosis, decompensation and hepatocellular carcinoma.

    Time frame: 10 years

Secondary outcomes

  1. Genotype profile in Chinese patients of each disease

    Time frame: 10 years

  2. Natural history of Chinese patients with each disease of different genotype

    Time frame: 10 years

  3. Causes of death in Chinese patients of each disease

    Time frame: 10 years

Other outcomes

  1. Quality of life

    Time frame: 10 years

07

Study locations

12 of 12 sites recruiting
08

References and documents

Publications

  • Xu A, Lv T, Zhang B, Zhang W, Ou X, Huang J. Development and evaluation of an unlabeled probe high-resolution melting assay for detection of ATP7B mutations in Wilson's disease. J Clin Lab Anal. 2017 Jul;31(4):e22064. doi: 10.1002/jcla.22064. Epub 2016 Sep 17. PubMed 27638368 ↗
  • Lv T, Li X, Zhang W, Zhao X, Ou X, Huang J. Recent advance in the molecular genetics of Wilson disease and hereditary hemochromatosis. Eur J Med Genet. 2016 Oct;59(10):532-9. doi: 10.1016/j.ejmg.2016.08.011. Epub 2016 Aug 31. PubMed 27592149 ↗
  • Zhang W, Li Y, Xu A, Ouyang Q, Wu L, Zhou D, Wu L, Zhang B, Zhao X, Wang Y, Wang X, Duan W, Wang Q, You H, Huang J, Ou X, Jia J; China Registry of Genetic/Metabolic Liver Diseases (CR-GMLD) Group. Identification of novel non-HFE mutations in Chinese patients with hereditary hemochromatosis. Orphanet J Rare Dis. 2022 Jun 6;17(1):216. doi: 10.1186/s13023-022-02349-y. PubMed 35668470 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2015 (actual). Primary completion is estimated for Apr 2022, 82 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2017
First posted
Apr 27, 2017
StartActual
Jun 13, 2015
Primary completionEst.
Apr 28, 2022
CompletionEst.
Apr 28, 2027
Last update
Apr 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03131427
Collaborators
Beijing YouAn Hospital, Henan Provincial People's Hospital, Beijing Ditan Hospital, Hebei Medical University Third Hospital, Peking University First Hospital, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Nanfang Hospital, Southern Medical University, Logistics University of Chinese People's Armed Police Forces, Beijing Anzhen Hospital, West China Second University Hospital, Jinshan Hospital Fudan University, Fudan University
Responsible party
Jidong Jia (Liver Research Center, Beijing Friendship Hospital) — Principal investigator
First posted
Apr 27, 2017
Start date
Jun 13, 2015
Primary completion
Apr 28, 2022 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Apr 27, 2017

Study contacts

Jidong Jia, MD
Contact
jia_jd@ccmu.edu.cn
010-63139816
Xiaojuan Ou, MD
Contact
ouxj16@sina.com
010-63138315
Jidong Jia, Doctor
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion